Recruiting ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL NCT07342478 Conditions CLL, CLL (Chronic Lymphocytic Leukemia), CLL / SLL, +23 more Locations The Center for Cancer and Blood Disorders-Bethesda — Bethesda, Maryland, United States Optum Medical Group (Rhodes) P.C. — Las Vegas, Nevada, United States OSU Comprehensive Cancer Center — Columbus, Ohio, United States UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States View Trial Details
Completed REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy NCT05621148 Conditions Bruton Tyrosine Kinase Inhibitor, CLL, Refractory, CLL, Relapsed, +5 more Locations CHU Estaing - Hématologie Clinique Adulte — Clermont-Ferrand, France Centre Léon Bérard - Hématologie — Lyon, France Institut Paoli-Calmettes - Hématologie Clinique — Marseille, France MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique — Montpellier, France View more locations Show fewer locations Loading locations... View Trial Details
Completed Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia NCT04512105 Conditions AML, Adult, Acute Myeloid Leukemia, CLL, +22 more Locations Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California, United States View Trial Details
